At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
Resolute Onyx Stent - 2.0 mmdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent Resolute Onyx 2.0 mm Clinical Study
In Brief
A clinical study evaluating Resolute Onyx Stent - 2.0 mm for Coronary Artery Disease. Completed, enrolled 101 participants across 17 sites.
Detailed Summary
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries that allows the use of a 2.0 mm diameter stent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedApr 2015
Primary CompletionFeb 2017
Study CompletionFeb 2019
TodayJul 2026
First PostedApr 9, 2015
Enrollment StartApr 6, 2015
Primary CompletionFeb 13, 2017
Study CompletionFeb 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.2 years ago
Interventions
Resolute Onyx Stent - 2.0 mmdevice
Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent